Replies to post #7393 on Vericel Corp. (VCEL)

[commoncentsinvestor]

Happy New Year manisero.

Colangelo has stated many times that their immediate intention is to put all of their efforts into expanding revenues for their currently approved products MACI & Epicel. ixCell will only be moved forward in the immediate future if they partner with someone who is willing to pay the costs of completing Phase III. Since ixCell has already received Fast Track, Orphan, and RMAT status, chances of that happening are probably pretty good.

Personally I have never included anything in my estimates of the companies worth or estimates of future revenues for ixCell. If it actually happens, it could dramatically increase the share price.

[Lunacy_John Galt]

The FDA required study is for Pediatric MACI patients, not ixmyelocel-T. Yes, the ICT $ will help with these costs.